Anifrolumab in systemic lupus erythematosus: real-world evidence from a Spanish multicentre cohort of 206 patients and literature review - PubMed
7 hours ago
- #anifrolumab
- #systemic lupus erythematosus
- #real-world evidence
- Anifrolumab is approved for adults with moderate-to-severe active systemic lupus erythematosus (SLE).
- Real-world evidence (RWE) remains limited despite efficacy and safety demonstrated in randomized clinical trials (RCTs).
- A Spanish multicentre study included 206 SLE patients (183 women; mean age 44.6±12.6 years).
- Common indications for anifrolumab were cutaneous (61.7%), musculoskeletal (48.5%), and haematological (27.2%) manifestations.
- Rapid and sustained improvement was observed in disease activity, serological markers, and corticosteroid tapering.
- Organ damage remained stable during treatment.
- Most frequent adverse events were herpes zoster (n=5), respiratory infections (n=6), and headache (n=3).
- 20 patients discontinued treatment.
- Anifrolumab demonstrated early and sustained clinical benefit with a favourable safety profile.
- Findings support the incorporation of anifrolumab into routine care for SLE patients.